NASDAQ: BTMDBiote Corp Stock
$2.92-0.06 (-2.01%)
Updated Aug 15, 2025
BTMD Price
$2.92
Fair Value Price
N/A
Market Cap
$144.36M
52 Week Low
$2.76
52 Week High
$6.98
P/E
2.95x
P/B
-1.7x
P/S
0.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$199.07M
Earnings
$31.31M
Gross Margin
71.9%
Operating Margin
23.15%
Profit Margin
15.7%
Debt to Equity
-2.16
Operating Cash Flow
$41M
Beta
0.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BTMD Overview
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BTMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
BTMD
Ranked#21 of 42
Ranked#21 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.56 | A | |
| $16.04 | A | |
| $7.08 | A |
Be the first to know about important BTMD news, forecast changes, insider trades & much more!
BTMD News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BTMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BTMD is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BTMD is good value based on its earnings relative to its share price (2.95x), compared to the US market average (35.99x)
P/E vs Market Valuation
BTMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BTMD due diligence checks available for Premium users.
Valuation
BTMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.95x
Industry
15.59x
Market
35.99x
BTMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BTMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BTMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.7x
Industry
4.78x
BTMD's financial health
Profit margin
Revenue
$48.9M
Net Income
$3.2M
Profit Margin
6.5%
BTMD's Earnings (EBIT) of $46.09M... subscribe to Premium to read more.
Interest Coverage Financials
BTMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$104.8M
Liabilities
$183.6M
Debt to equity
-2.16
BTMD's short-term liabilities ($50.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BTMD's long-term liabilities ($133.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BTMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BTMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.1M
Investing
-$2.0M
Financing
-$27.2M
BTMD's operating cash flow ($41.48M)... subscribe to Premium to read more.
Debt Coverage Financials
BTMD vs Medical Care Facility Stocks
Biote Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.